{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:05:48Z","timestamp":1792325148372,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eclinm.2026.104091","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:09:40Z","timestamp":1785143380000},"page":"104091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Safety and efficacy of topical OCS-01 ophthalmic suspension for the treatment of diabetic macular oedema: stage 1 of a multicentre, double-blind, randomised, vehicle-controlled phase 2\/3 trial"],"prefix":"10.1016","volume":"98","author":[{"given":"Arshad M.","family":"Khanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Tadayoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabri","family":"Markabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2631-7754","authenticated-orcid":false,"given":"Hani","family":"Salehi-Had","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9219-1614","authenticated-orcid":false,"given":"David S.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.104091_bib1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eclinm.2026.104091_bib2","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema","volume":"103","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.eclinm.2026.104091_bib3","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.4103\/ijo.IJO_1240_18","article-title":"Diabetic macular edema: evidence-based management","volume":"66","author":"Browning","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.eclinm.2026.104091_bib4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eclinm.2026.104091_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2010.12.033","article-title":"Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"118","author":"Elman","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eclinm.2026.104091_bib6","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.ophtha.2012.02.010","article-title":"One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema","volume":"119","author":"Do","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eclinm.2026.104091_bib7","first-page":"8","article-title":"Aflibercept: how does it compare with other anti-VEGF drugs","volume":"1","author":"Sharma","year":"2014","journal-title":"Austin J Clin Ophthalmol"},{"key":"10.1016\/j.eclinm.2026.104091_bib8","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eclinm.2026.104091_bib9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.104091_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.eclinm.2026.104091_bib11","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eclinm.2026.104091_bib12","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eclinm.2026.104091_bib13","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","article-title":"Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema","volume":"119","author":"Campochiaro","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eclinm.2026.104091_bib14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eclinm.2026.104091_bib15","series-title":"Clinical practice recommendations for managing diabetic macular edema","year":"2019"},{"key":"10.1016\/j.eclinm.2026.104091_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/2474126419834711","article-title":"Evidence-based guidelines for management of diabetic macular edema","volume":"3","author":"Bakri","year":"2019","journal-title":"J Vitreoretinal Dis"},{"key":"10.1016\/j.eclinm.2026.104091_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European Society of retina specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.eclinm.2026.104091_bib18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"del Amo","year":"2017","journal-title":"Progress Ret Eye Res"},{"key":"10.1016\/j.eclinm.2026.104091_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/aos.14861","article-title":"Nanoparticle eye drops deliver therapeutic drug concentrations to both anterior and posterior segment","volume":"100","author":"Loftsson","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.eclinm.2026.104091_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/aos.15215","article-title":"Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: a randomized, double-masked, vehicle-controlled study","volume":"101","author":"Stef\u00e1nsson","year":"2023","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.eclinm.2026.104091_bib21","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.ophtha.2010.02.033","article-title":"Evaluation of the age-related eye disease study clinical lens grading system AREDS report No. 31","volume":"117","author":"Chew","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eclinm.2026.104091_bib25","article-title":"Diabetic macular edema management: a review of anti-vascular endothelial growth factor (VEGF) therapies","volume":"16","author":"Cheema","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.eclinm.2026.104091_bib22","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104091_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ajo.2018.07.030","article-title":"Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in Protocol T","volume":"195","author":"Bressler","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.eclinm.2026.104091_bib24","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eclinm.2026.104091_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100557","article-title":"Demographic and metabolic risk factors associated with development of diabetic macular edema among persons with diabetes mellitus","volume":"4","author":"Haliyur","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.eclinm.2026.104091_bib30","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","article-title":"Prevalence of and risk factors for diabetic macular edema in the United States","volume":"132","author":"Varma","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.eclinm.2026.104091_bib31","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity. a randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:29:05Z","timestamp":1787560145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026003445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"alternative-id":["S2589537026003445"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104091","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of topical OCS-01 ophthalmic suspension for the treatment of diabetic macular oedema: stage 1 of a multicentre, double-blind, randomised, vehicle-controlled phase 2\/3 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104091"}}